BTW, CSL had a safety problem with the 1st gen plasma derived drug in phase II and started all over with CSL-112.The higher-dosage CSL-111 treatment group was discontinued early because of liver function test abnormalities. http://www.ncbi.nlm.nih.gov/pubmed/17387133